U.S. Markets open in 5 hrs 11 mins

The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings

Shanthi Rexaline

Biotech stocks pulled back in last week. Incidentally, some large-cap biotech stocks were hitting new peaks even amid the sectoral downturn.

New molecular entity approval hit a new peak at 55 thus far this year, compared to 46 in 2017.

With that said, here are some catalytic events that can move biotech stocks this week.


  • 26th Euro Congress and Expo on Dental & Oral Health - Dec. 10-11, in Rome, Italy
  • 11th World Congress on Hormonal Imbalance and hormone Replacement Therapy – Dec. 13-14, in Dubai, UAE
  • 13th International Conference on Allergy and Clinical Immunology – Dec. 13-14, in London, UK
  • International Conference on Mental Health in Adults and Childhood – Dec. 13-14, in Abu Dhabi, UAE
  • 4th International Anesthesia and Pain Medicine Conference – Dec. 13-14, in Abu Dhabi
  • 13th Annual Conference on Dementia and Alzheimers Disease - Dec. 13-15, in Abu Dhabi
  • 12th World Pediatric Congress – Dec. 13-15, in Abu Dhabi, UAE
  • ESMO Immuno-oncology Congress 2018 – Dec. 13-16, in Geneva Switzerland

Clinical Trial Results

Denali Therapeutics Inc (NASDAQ: DNLI) is scheduled to present Phase 1 data for its Alzheimer's disease candidate DNL747 at its R&D Day Monday, Dec. 10. The company released positive results from the trial Nov. 19. Denali said it plans to evaluate the candidate in multiple indications, including Alzheimer's, amyotropic sclerosis and multiple sclerosis.

Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) is expected to report preliminary results from the lower-dose cohorts of the Phase 1/2 study of BPX-601 in patients with advanced pancreatic cancer at the ESMO Immuno-oncology conference scheduled for Dec. 13-16.

View more earnings on IBB

Apellis Pharmaceuticals Inc (NASDAQ: APLS) is due to present an update on the Phase 3 study of APL-2 in geographic atrophy related to age-related macular degeneration in the first-half of December.

Idera Pharmaceuticals Inc (NASDAQ: IDRA) will present an update on its ILLUMINATE 204 Phase 1/2 trial in the first-half of December. The trial is evaluating its intratumoral tilsotolimod in combination with either ipilimumab or pembrolizumab in patients with PD-1 refractory/relapsed metastatic melanoma


Monday, Dec. 10

  • Avid Bioservices Inc (NASDAQ: CDMO) (after the market close)

Tuesday, Dec. 11

  • Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) (after the market close)

Thursday, Dec. 13

  • Pure Bioscience, Inc. (OTC: PURE) (after the market close)

Related Links:

Wedbush Moves To The Sidelines On Tesaro Following Glaxo Deal

Novelion Rises 50% After Activist Investor Demands Exploration Of Strategic Alternatives

See more from Benzinga

© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.